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Abstract
Background: The identification of additional prognostic markers to improve risk stratification and to avoid overtreatment is
one of the most urgent clinical needs in prostate cancer (PCa). MicroRNAs, being important regulators of gene expression,
are promising biomarkers in various cancer entities, though the impact as prognostic predictors in PCa is poorly understood.
The aim of this study was to identify specific miRNAs as potential prognostic markers in high-risk PCa and to validate their
clinical impact.
Methodology and Principal Findings: We performed miRNA-microarray analysis in a high-risk PCa study group selected by
their clinical outcome (clinical progression free survival (CPFS) vs. clinical failure (CF)). We identified seven candidate miRNAs
(let-7a/b/c, miR-515-3p/5p, -181b, -146b, and -361) that showed differential expression between both groups. Further qRT-
PCR analysis revealed down-regulation of members of the let-7 family in the majority of a large, well-characterized high-risk
PCa cohort (n = 98). Expression of let-7a/b/and -c was correlated to clinical outcome parameters of this group. While let-7a
showed no association or correlation with clinical relevant data, let-7b and let-7c were associated with CF in PCa patients
and functioned partially as independent prognostic marker. Validation of the data using an independent high-risk study
cohort revealed that let-7b, but not let-7c, has impact as an independent prognostic marker for BCR and CF. Furthermore, we
identified HMGA1, a non-histone protein, as a new target of let-7b and found correlation of let-7b down-regulation with
HMGA1 over-expression in primary PCa samples.
Conclusion: Our findings define a distinct miRNA expression profile in PCa cases with early CF and identified let-7b as
prognostic biomarker in high-risk PCa. This study highlights the importance of let-7b as tumor suppressor miRNA in high-risk
PCa and presents a basis to improve individual therapy for high-risk PCa patients.
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Introduction
Prostate cancer (PCa) is the most common malignancy among
men in Europe, with an estimated incidence of 345,900 in 2006
[1]. The natural course of the disease is heterogeneous, varying
from indolent to highly aggressive cancer that metastasizes at early
stage causing pain and untimely death. Current risk stratifications
like low2/intermediate2/and high-risk PCa alone are insufficient
to predict clinical outcome. Even men with high-risk PCa (PSA
.20 ng/ml and/or biopsy Gleason Score $8 and/or clinical
stage $ T3) represent a heterogeneous group of patients. Even
though characterized as a group that has poorest clinical outcome
among all risk groups, only up to 30% develop metastases and die
due to their disease [2–4]. Therefore, new prognostic biomarkers
are urgently needed to better sub-stratify risk groups, identify the
lethal disease, eventually avoid overtreatment, and improve
individual therapy. The identification of prognostic markers,
especially for the lethal disease, is hardly possible in an unselected
PCa collective. Although high-risk PCa cohorts now show much
better than expected outcomes, they still represent an ideal group
to identify factors specifically correlated with the lethal disease.
There is growing evidence that microRNAs (miRNA) are
suitable candidates for the development of such biomarkers.
MiRNAs are small non-coding RNA strands that regulate
expression of genes at the post-transcriptional and the translational
level. Individual miRs have been characterized either as tumor
suppressors or oncogenes (oncomiRs) [5].
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Several reports describe PCa-specific miRNA expression
signatures, however the kind of regulated miRNAs is diverse.
Agreement exists among these studies in that the majority of
miRNAs are down-regulated in the PCa samples [6–10]. Although
a correlation to tumor stage and grade was described for several
miRs their relevance as prognostic markers to predict hard clinical
endpoints, like clinical failure or cancer-related death, remains
limited [8,11–14]. However, there are promising approaches to
detect coherence between altered expression of specific miRNAs
and progression of the disease. Larne and coworkers recently
identified a miRNA-based multimarker model as prognostic tool
for progression in PCa [15]. Our working group previously
described miR-221 to be a prognostic marker for disease
recurrence in high-risk PCa [16].
Some of the most frequently mentioned miRs that show down-
regulation in PCa are members of the let-7 family [6,9,17,18]. This
family consists of several members, whose diversity is distinct by
isoforms (let-7a-g,-i, miR-98). The expression of some let-7 members
was shown to be down-regulated in various other cancer entities as
well, such as breast, ovarian, and lung cancer [19–21]. Known
relevant targets of let-7 are oncogenes like Ras, cmyc, EZH2 and
HMGA2 [17,22–24], indicating a tumor-suppressive function of let-
7 by regulating oncogenes specifically involved in growth and self-
renewing capacity of PCa cells. More recently it was shown that
PCa stem cells are characterized by down-regulation of let-7 family
members and that let-7 is critically involved in tumorigenicity by
controlling androgen receptor signaling, proliferation and differ-
entiation [25–27]. However, a role of let-7 family members as
prognostic markers in PCa has not been described up to now.
The aim of this study was to identify miRNAs differentially
expressed in high-risk PCa with diverse clinical outcome. We
detected a pattern consisting of 7 miRNAs associated with early
clinical recurrence and identified let-7 family members to be
progressively down-regulated in aggressive tumors. In a large high-
risk PCa cohort we confirmed these results and demonstrated that
down-regulation of let-7b is correlated with biochemical recurrence
and clinical failure. Furthermore, we confirmed let-7b as indepen-
dent prognostic marker in high-risk cancer in an independent
validation cohort. In addition we showed that expression of
HMGA1, a non-histone protein, is regulated by let-7b by binding to
the 59UTR of HMGA1. Our results demonstrate that high-risk
PCa is characterized by a specific miRNA profile and that
individual let-7 family members are promising prognostic markers
in this patient group.
Materials and Methods
Patient Cohorts
We worked with three diverse PCa collectives for our analyses:
Cohort A consists of 98 formalin fixed and paraffin embedded
(FFPE) tissue specimen of a well-characterized group of high-risk
PCa patients [16]. See table 1 for clinic-pathological data. Tissue
samples and clinical data were utilized for microarray and qRT-
PCR analyses on microRNAs as well as subsequent correlation
and association studies.
Cohort B consists of 92 FFPE samples from RP. Tissue
specimen and clinic-pathological data were obtained from the
Department of Urology at the University Hospital Leuven,
Belgium (Table 1). This group served as validation collective to
confirm the role of let-7b as prognostic marker.
Preoperative staging in cohort A and B included DRE, an
abdominopelvic-computed tomography (CT) scan and a bone
scan. Neoadjuvant hormonal treatment, radiation or chemother-
apy was an exclusion criterion. Lymph node metastasis and
prostate specimens (whole mount sections, 4 mm intervals) were
staged and graded according to the 2002 TNM classification and
the Gleason grading system as previously described [16]. Follow-
up was performed every 3 months for the first 2 years after
surgery, every 6 months in the following 3 years, and annually
thereafter. Biochemical relapse (BCR) was defined as PSA
$0.2 ng/ml on 2 consecutive follow-up visits. Clinical failure
was declared when either local or distant metastases were
histologically proven or confirmed by CT or bone scan. Overall
survival (OS) was defined as time from RP to death attributed to
PCa or complications of the disease.
Benign prostatic hyperplasia (BPH) samples were derived from
prostate adenomectomy specimens. Samples were paraffin-em-
bedded as well; regions with .80% adenoid tissue were used. All
patients had normal PSA levels before surgery and carcinoma was
excluded by histopathology.
Cohort C consists of 21 cancer samples obtained from the
Department of Urology at the University Hospital Wuerzburg,
Germany. Pairs of fresh frozen PCa tissue and adjacent benign
tissue, were used for mRNA and miRNA isolation. This group
contains patients with unselected histo-pathological PCa specimen
(high-, intermediate-, and low risk cancer). Since mRNA isolation
of fresh frozen tissue specimen is more effective compared to
isolation on FFPE samples we worked with this cohort for
correlation studies on expression of HMGA1 and let-7b. For this
analysis clinic-pathological data were irrelevant and therefore not
shown. Histological evaluation was performed by a Senior
pathologist (P.S.). Cancerous samples containing at least 80%
Table 1. Clinico-pathological features of both high-risk PCa
groups (cohort A – test group and cohort B – validation
group).
Cohort A (n =98) Cohort B (n=92)
Clinic-pathological features n (%) n (%)
age, years (range) 66 (47–78) 64 (41–76)
follow-up, months (st.dev) 78 (638) 111 (645)
pre-operative PSA (ng/ml)
mean (range) 48 (20–156) 22 (1–95)
Gleason Score
#6 3 (3.1%) 26 (28.3%)
7 39 (39.8%) 46 (50%)
8 15 (15.3%) 12 (13%)
9 29 (29.6%) 8 (8.7%)
10 12 (12.2%) 0 (0%)
pathological tumor stage
pT2 16 (16.3%) 29 (31.5%)
pT3a 23 (23.5%) 36 (39.1%)
pT3b 42 (42.9%) 21 (22.9%)
pT4 17 (17.3%) 6 (6.5%)
lymph node
positive 34 (34.7%) 10 (10.9%)
negative 64 (65.3%) 82 (89.1%)
clinical failure
yes 18 (18.4%) 14 (15.2%)
no 80 (81.6%) 78 (84.8%)
doi:10.1371/journal.pone.0065064.t001
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malignant cells were used for further analyses. Areas with at least
80% ducts and no cancerous cells were selected for adjacent
benign tissue.
The studies were approved by the local ethics committee of the
medical faculty of the University of Wuerzburg, Germany (no. 59/
04) and the Catholic University Leuven, Belgium (UZ Leuven
Study number S54424; Belgian Study number B322201214832);
all patients provided written informed consent.
Microarray Analysis
To screen for candidate miRs, being correlated with poor
outcome 6 BPH tissues and 13 high-risk PCa specimens were
hybridized to microarrays (cohort A). High-risk PCa specimens
were subdivided into two groups (group 1: CPFS (n = 7); group 2:
CF (n = 6) (see Table 2 for details). A set of 668 miRs (Probe Set
1564V2 miRVana Applied Biosysems) was spotted on Nexter-
ionTM HiSense E microarray slides in quadruplicates. We used the
Pure-Link FFPE Total RNA Isolation Kit and the RiboMinus
Concentration Module (Invitrogen) for RNA purification. Slide
processing was performed according to the Applied Biosystems
miRVanaTM manuals. The microarray data is available under
GEO accession number GSE18671.
RNA Extraction and Reverse Transcription
Total RNA extraction from paraffin-embedded or frozen tissue
samples and PCa cell lines were performed using the Recover all
Total Nucleic Acid Isolation Kit and the Total RNA Extraction
Kit respectively (Ambion and miRNeasy Mini Kit, Qiagen).
Specific cDNA was synthesized from total RNA with stem-loop
reverse transcription primers according to the TaqManH miR
assay protocol (PE Applied Biosystems). Unspecific cDNA
synthesis was performed with ImProm-IITM Reverse Transcrip-
tion System (Promega) according to the ABsolute QPCR SYBR
Green protocol (Thermo Scientific).
qRT-PCR
Confirmation of the microarray results on independent samples
and on an increased sample size was done using qRT-PCR.
M(i)RNA expression in tissue samples and cell lines was quantified
with either TaqManH (miR) or SYBR Green (mRNA) assay kits
and the BioRad OPTICON 2, following the manufacturer’s
instructions (BioRad). Primers for let-7a-d, miR-16, -29a, -221, -
146b, and -181b were obtained from Applied Biosystems; small
nuclear RNA RNU6B was applied for normalization. b-Actin
served as housekeeper for HMGA1 expression (Applied Biosys-
tems). Relative m(i)RNA-expression was calculated with the
Table 2. Clinic-pathological features of 13 high-risk PCa patients (cohort A) separated by clinical outcome (group 1: high-risk
PCa+CPFS; group 2: high-risk PCa+CF).
Clinic-pathol. features Group 1 Group 2
High-risk PCa+CPFS (n=7) High-risk PCa+CF (n =6)
age, years (range) 64 (52–74) 66 (57–71)
follow-up, months (st.dev) 106 (634.1) 72.6 (625.9)
pre-operative PSA (ng/ml) 52.27 (21–79) 63.96 (24–125)
Gleason Score
6 3 0
7 4 0
8 0 0
9 0 1
10 0 5
pathol. tumor stage
pT2b 1 0
pT3a 1 0
pT3b 3 1
pT4 2 5
surgical margin status
pos. 6 6
neg. 1 0
biochemical relapse
yes 3 6
no 4 0
clinical failure
yes 0 6
no 7 0
cancer-related death
yes 0 3
no 7 3
doi:10.1371/journal.pone.0065064.t002
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comparative DCt-method (DCt sample = Ct sample - Ct RNU6B).
The 2–DDCt method was used to assess fold changes in m(i)R-
expression between samples and controls. Mean Ct was deter-
mined from triplicate PCR experiments. Standard deviation was
#0.4, p values ,0.05 were considered significant.
Cell Culture and Transient Transfection
LNCaP and PC-3 cells were obtained from ATCC, Germany
using passages 5 to 35. Cells were grown at 37˚C in a humidified
incubator at 5% CO2. Cells were seeded and simultaneously
transfected in 6-well plates at a density of 3.56105 per well using
RPMI 1640 Medium Gibco without Phenolred, containing 10%
fetal calf serum (Invitrogen), Glutamax (Invitrogen), NEAA
(Gibco), HEPES Buffer solution (PAA), and Sodium pyruvate
solution (PAA). Transient transfection was performed using
LipofectamineTM reagent (Invitrogen) and Opti-MEMH (Invitro-
gen-Gibco) following the supplier’s instructions. Precursor-
respectively antigo let-7b was applied to induce or suppress let-7b
expression, pre- and anti-negative let-7b (Applied Biosystems) were
used for control transfection. Cells were harvested 48 h after
transfection.
Western Blot
Cells were lysed in Cytobuster or Phosphosafe (Novagene) after
preparation and determination of equal amounts proteins were
separated on SDS-PAGE and later transferred to Nitrocellulose
membrane (Bio-Rad). For protein expression of HMGA1 we used
1 mg/ml goat polyclonal antibodies (HMGA1a/1b, Abcam); b-
Actin (Abcam) served as housekeeper. For visualization we used
horseradish peroxidase-coupled secondary antibodies (Abcam and
Dako) and the ECL Plus kit (GE Healthcare). For quantification of
band intensity we used Image J (http://imagej.nih.gov/ij/).
Luciferase Assay
The 39UTR of the human HMGA1 gene was PCR-amplified
using the following primers that contained additional Hind III or
Spe I sites: HMGA1Hindfor: 59-GATC AAGCTTCA-
TATTGTGGTGATGGAG-39; HMGA1SpeIrev: 59-CAAT AC-
TAGT GAACATTTGGCGCTGGTAG-39. The resulting
HMGA1 PCR fragment containing the two most downstream
located let-7b complementary sites to HMGA1 was cloned
downstream of the Renilla luciferase stop codon into a luciferase
reporter plasmid (pMIR- REPORT-Luciferase, Apllied Biosys-
tems) using the Hind III and Spe I sites. To perform luciferase
assays LNCaP cells were seeded in 6-well plates at a density of
3.56105 per well and incubated for 24 hours. The reporter vector
was co-transfected into LNCaP cells with a control non-targeting
RNA oligonucleotide or let-7 precursor miRNA. Transient
transfection was performed using LipofectamineTM reagent
(Invitrogen). 48 hours post transfection the luciferase activity was
analyzed by Dual-LuciferaseH Reporter Assay System (Promega).
Renilla activity was used for normalization and as a control for
transfection efficiency.
Statistical and Bioinformatics Analysis
Microarray-Analysis: Spot intensities from scanned slides were
quantified using ScanAlyze Software (http://rana.lbl.gov/
EisenSoftware.htm). Data were analyzed with different R packages
from the Bioconductor project (www.bioconductor.org). Resulting
signal intensities were normalized by variance stabilization [28].
Differentially expressed genes were selected from the microarray
data by limma (Linear models for microarray Analysis) package
[29].
qRT-PCR-Analysis: Samples were compared with a Welch
Two Sample t-test. Prior to further analysis of collective A, z-scores
of the relative expression values were created. Subsequently, the
optimal cut-off point for let-7 expression was determined by
receiver operating characteristic (ROC) curve analysis (R-package
‘pROC’). Based on the resulting threshold the expression values
were dichotomized. The associations between expression and
clinical recurrence were determined by Cox regression with uni-
and multivariate models. The Kaplan-Meier method was used to
estimate the survivor function at various time points. Univariate
and multivariate hazard ratios and their 95% confidence intervals
(CI) were estimated using the Cox proportional hazards model
(Bioconductor package ‘survival’). P values ,0.05 were considered
significant. To test, whether this approach is applicable to an
independent test dataset, z-scores were created for collective B.
However, for dichotomization the threshold derived from
collective A was used. All subsequent steps were performed as
described for collective A. For correlation between HMGA1 and
let-7b Pearson correlation was calculated.
Results
Cancer Specific miRNA Expression Status in High-risk PCa
We performed microarray analysis of miRNA isolated from six
paraffin-embedded BPH and 13 PCa samples to screen for
candidate miRNAs being associated with the development or
progression of high-risk disease. The analyzed PCa cases were part
of a well-characterized high-risk collective (cohort A) (Table 1) and
were selected based on their clinical outcome. The pre-selected
PCa cases were separated into two groups by clinical failure and
follow-up without recurrence of the disease (group 1: CPFS vs.
group 2: CF). Table 2 shows the cancer characteristics of both
groups.
The goal of this analysis was to screen for a specific miRNA
signature of high-risk cancer patients with disease recurrence.
Initially we compared miRNA expression in all 13 high-risk PCa
cases together to that of the benign disease. Of all differentially
expressed miRNAs (expression fold change .1.5 and p value
,0.05) the majority of 61 miRs were down-regulated and 21 miRs
were up-regulated in the high-risk disease. See Table S1 for listing
of all up- and down-regulated miRNAs. Hierarchical clustering,
based on the selected 82 differentially expressed miRNAs,
generated a tree with clear distinction between the malignant
disease and the benign hyperplasia (Fig. 1A). Even though
comparison was performed only between the benign and the
malignant disease, a sub-grouping of the tumors based on their
clinical outcome was evident.
To perform a technical validation of the array results we
analyzed the expression of three of the most differentially
expressed miRNAs, among others. As shown in Figure 1B and
2B we could confirm the significant down-regulation of let-7a/b/c,
miR-16, -29a, -146, -181 and -221 prior seen in the array data by
qRT-PCR.
MiR Expression Profile of High-risk PCa with Diverse
Clinical Progression-free Survival
Based on the separation of both risk groups by cluster analysis
we hypothesized to find a miRNA profile in PCa cases with
progressive disease. Therefore, we analyzed the microarray data
with regard to miRs that were differentially expressed in both
high-risk groups (fold change .1.5 and P value ,0.05). The Venn
diagram in Figure 2A and Figure S1 visualize the plotting of all
human miRs that were differentially expressed in BPH tissue, in
high-risk PCa tissue with CPFS, and in high-risk tissue with CF. In
Let-7 in High-Risk Prostate Cancer
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total, 148 miRs were diversely expressed within all three tissue
types. The expression of seven miRNAs (namely let-7a/c, miR-515-
3p/5p, -181b, -146b, and -361) were found to be significantly
different between all three groups analyzed (BPH, group 1 and 2)
indicating a specific miRNA profile for high-risk PCa with
progressive disease. 47 miRNAs showed different expression in
group 1 vs. group 2; among the top ten most differentially
expressed miRNAs we found several members of the let-7 family
(Fig. S1).
Using RT-PCR analysis expression differences between BPH,
group 1 and 2 for let-7a, let-7c, miR-146b, and -181b could be
confirmed (Fig. 2B). Since expression of let-7b and -d was shown to
discriminate at least two of the three tissue types we included both
let-7 family members in further analyses. As predicted by the array
data, the let-7 family members showed a progressive down-
regulation from benign to malignant (group 1) and further to the
aggressive disease (group 2), whereas expression of miR-146b and -
181b was lowest in group 1 (Fig. 2B). Let-7d expression was hardly
detectable by RT-PCR and was, therefore, excluded in further
investigations.
Expression of let-7a/b/c is Significantly Down-regulated
in High-risk PCa
By microarray and RT-PCR analyses we identified some let-7
family members (let-7a-c) as potential candidate miRs for
diagnostic and prognostic markers in high-risk PCa.
We now wanted to confirm these results by qRT-PCR
experiments on our entire high-risk cohort A (n = 98). Statistical
analysis of the qRT-PCR data confirmed a significant down-
regulation of let-7a-c in the high-risk PCa cases compared to
benign hyperplasia (p#0.001) (Fig. 3A). In about 81/84/and 96%
of the tissue samples analyzed, the expression of let-7a/b and -c,
respectively, was below the median expression of the BPH samples
(Fig. 3B), indicating the tumor-specific value of the let-7 family
members in patients with high-risk prostate cancer.
Down-regulation of let-7b is Associated with Aggressive
Cancer Characteristics
Based on the assumption that some let-7 family members are
progressively down-regulated in the more aggressive PCa cases
(group 2), we postulated that down-regulation of let-7 might also be
associated with clinic-pathological features or prognosis of PCa
patients. Therefore, we looked for correlation between let-7a/b/c
expression and tumor characteristics of the PCa collective A like
Gleason Score (7# GS $8), pathological tumor stage (3a #pT
$3b) and clinical endpoints like BCR, CF, and CRD (see Table 2).
We found progressive down-regulation of let-7b in patients with
poor cancer characteristics like high Gleason Score ($8),
biochemical relapse and clinical failure (p,0.05) (Fig. 3C).
However, expression of let-7c was correlated with CF only. No
correlation was seen between let-7b or -7c expression and
pathological tumor stage (3a #pT $3b) or CRD (Fig. 3C). Since
let-7a lacked any significant results in terms of cancer character-
istics and clinical endpoints we neglected this miR in our further
analyses (Fig. S2).
Let-7b and let-7c as Prognostic Marker for Progression in
a High-risk PCa Collective (cohort A)
To determine whether let-7b or -7c could serve as a prognostic
indicator for biochemical relapse or clinical failure we dichoto-
mized a high-risk study group (cohort A) in low and high let-7b/c
expression based on z-scores. Kaplan-Meier estimates showed a
significant difference between groups of high and low let-7b
expression in BCR (log rank p = 0.01), while let-7c showed
borderline significance (log rank p = 0.08) (Fig. 4A). The 10 yr
biochemical progression-free survival rate was 65% and 37% for
high and low let-7b expression, respectively. For let-7b and let-7c
Kaplan-Meier estimates also predicted a significant difference
between groups of high and low expression in CF (log rank
p,0.001) (Fig. 4A). 14 of 38 patients (37%) with low let-7b
expression, but only 5 of 60 patients (8.3%) in the high let-7b
expression group were found to have experienced CF.
Cox regression analysis showed that let-7b but not let-7c
expression was univariately significant for the prediction of BCR
(HR 0.36 (0.16–0.82)). When let-7b expression and Gleason Score
were considered together in a multivariate model both variables
independently predicted BCR. Eventually, we evaluated whether
let-7b or let-7c are independent markers for clinical failure in cohort
A. The expression of both miRs are univariately significant for the
prediction of clinical failure (Table 3). However, in a multivariate
Cox regression model only high Gleason Score but not let-7b or -c
were significantly correlated to poor prognosis.
In summary the Kaplan Meier estimates and Cox regression
analysis indicate that low let-7b and let-7c expression might be
correlated to BCR and CF in cohort A.
Validation of let-7b and let-7c as Prognostic Markers in an
Independent, External Testing Collective (cohort B)
To validate the role of let-7b and -c as prognostic markers we
worked with an independent collective of primary high-risk PCa
cases (cohort B). As already observed for cohort A we detected a
significant down-regulation of let-7b and let-7c in PCa samples
when compared to BPHs (Table S2). We created z-score levels
based on the analyzed DCt expression data of both let-7s in the
testing cohort. Subsequently we dichotomized the testing cohort
using the cut-off levels identified for collective A. Each sample was
predicted to be either on high or low risk for BCR or CF based on
these thresholds. We could not confirm the prognostic role of let-7c
as marker for progression in the testing cohort as indicated by
Kaplan Meier estimates and Cox regression analysis (Fig. 4b and
Table 4). Nevertheless, Kaplan Meier estimates indicated that
patients with low let-7b expression showed significantly shorter
cumulative time to BCR or CF than those with high let-7b
expression (Fig. 4b). To identify whether let-7b is an independent
prognostic covariate for progression of PCa we performed Cox
proportional hazard analysis. The multivariate Cox regression
model revealed let-7b, but not let-7c, to be an independent
prognostic marker for both: BCR (HR = 0.3 (0.15–0.61)) and CF
(HR = 0.23 (0.08–0.70) (Table 4).
Figure 1. Microarray analysis in high-risk PCa and BPH tissue. A. Microarray profiling of 6 BPH and 13 high-risk PCa tissue specimens (cohort
A). The latter were subdivided by clinical outcome: group 1: high-risk PCa+CPFS (n = 7); group 2: high-risk PCa+CF (n = 6). Row-wise scaled heatplot of
genes showing a fold change .1.5 and an adjusted p value ,0.05. Red indicating high expression, green low expression. Cancerous and non-
cancerous prostate tissues are clearly separated. Clustering indicates a distinction between group 1 and 2. B. Technical validation of the microarray
data by qRT-PCR. Relative expression ofmiR-16, -29a, and -221 was analyzed in 6 BPH (white) and 13 high-risk PCa samples (grey). MiRNA expression is
shown as means of BPH and high-risk PCa expression with error bars for standard deviation. *indicates p,0.01, p values were calculated using the
Welch 2 sample t-test.
doi:10.1371/journal.pone.0065064.g001
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Figure 2. MiRNA expression in high-risk PCa (cohort A) with early clinical failure. A. Venn diagram showing relationships between human
miRs that were expressed significantly different (61.5 fold) in PCa group 1 vs. PCa group 2 vs. BPH (adj p,0.05). Circles include numbers of up- or
Let-7 in High-Risk Prostate Cancer
PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e65064
down-regulated human miRs of each pair-wise comparison. Common miRs between different comparisons are shown in intersections. Grey boxes
indicate expression status of the let-7 family members. The table below lists all human miRs in which expression was significantly different either:
between (gr.1 vs. gr.2), (gr.2 vs. BPH) and (gr.1 vs. BPH) (red column); between (gr. 1 vs. gr. 2) and (gr. 2 vs. BPH) (green column); or between (gr. 1 vs.
gr. 2) and (gr. 1 vs. BPH) (blue column). All miRNAs are ranked based on the maximum expression fold change. The two columns aside the list of
miRNAs indicate an up- or down-regulation in expression (see arrows) and the dimension of expression fold change. B. Validation of the microarray
data by qRT-PCR. Relative expression of miR-146b, -181b, and let-7a/b/and -c was analyzed in 6 BPH (white), 7 high-risk PCa samples with CPFS (group
1) (light grey), and 6 high-risk PCa samples with CF (group 2) (dark grey). MiRNA expression is shown as means of expression in BPH and high-risk
tissue, respectively with error bars for standard deviation. *indicates p,0.01, p values were calculated using the Welch 2 sample t-test.
doi:10.1371/journal.pone.0065064.g002
Figure 3. Let-7a/b/c expression in a large high-risk PCa collective (cohort A) and its association to clinical data. A. Box- and whisker-plot
of relative expression of let-7a/b/c in 6 BPH (white bar) and 98 high-risk PCa (grey bar) tissue specimens. Expression was assessed by qRT-PCR. B.
Figure 3B summarizes the median expression of let-7a/b/c in 6 BPH and 98 PCa samples and shows corresponding standard deviation and the p
value. The median expression of the BPH samples was used as threshold. The percentage of PCa samples with down-regulated let-7 expression are
shown in the 6th column of the table. C. Box- and whisker-plot show expression of let-7b and -7c in 98 high-risk PCa tissue and 6 BPH specimens;
assessed by qRT-PCR. Subgroups are based on:N pathologic tumor features like Gleason Score and pathological tumor stage (GS #7, pT #3a – light
grey), (GS$8, pT$3b – dark grey) andN clinic-pathological characteristics like BCR, CF, CRD (no BCR/no CF/no CRD – light grey), (BCR/CF/CRD – dark
grey). A. + C. Let-7a/b/and -c expression is shown as means with error bars for standard deviation. *indicates p,0.01 (A) or p,0.05 (C). p values were
calculated using the Welch 2 sample t-test.
doi:10.1371/journal.pone.0065064.g003
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HMGA1 is a Direct Target of let-7b in PCa Cells
Expression and correlation studies of the high-risk cohort had
revealed let-7b to be a potential prognostic marker for progression in
high-risk PCa. Therefore, we searched for potential new target
genes using database target search programs (pictar, miRanda). A
binding site for let-7b was found in the 39UTR of HMGA1 suggesting
that this oncogene might be a target of let-7b (Fig. 5A). To determine
the relative level of let-7b and HMGA1 in prostate cancer cell lines
we performed qRT-PCR on LNCaP and PC-3 cells. We confirmed
results from a previous study showing that let-7b is expressed at very
low levels in PC-3 when compared to hormone sensitive LNCaP
cells [18]. Our results showed that HMGA1 expression is reduced in
LNCaP when compared to PC-3 cells indicating a reciprocal
expression of HMGA1 and let-7b in these PCa cell lines (Fig. 5B).
In addition, we analyzed the HMGA1 expression in PC-3 cells
48 hours after transient transfection with pre- and anti-let-7b by
qRT-PCR and Western Blot analysis. HMGA1-mRNA expression
was significantly lower after let-7b over-expression (p = 0.004)
(Fig. 5C). On protein level an inverse correlation was detected by
Western Blot analysis in PC-3 cells. Reintroduction of let-7b lead to
diminished HMGA1 protein expression compared to cells trans-
fected with pre-negative control (down-regulation to 64.4% in PC-
3). On the other hand, suppression of let-7b in these cancer cells
resulted in an up-regulation of HMGA1 up to 168.6% (Fig. 5C).
We performed luciferase reporter assay in LNCaP cells and found
the relative luciferase activity to be markedly diminished after let-7b
co-transfection. These results indicate that let-7b interferes with
HMGA1 translation via direct interaction with most downstream
located let-7b complementary sites of the 39UTR (Fig. 5D). We
herewith confirm HMGA1 to be a direct target of let-7b.
To compare whether HMGA1 expression was correlated to let-
7b in primary human PCa we isolated m(i)RNA of PCa and
adjacent benign tissue samples (cohort C) and performed qRT-
PCR analyses on let-7b and HMGA1. We utilized 21 pairs of PCa
samples in which expression of let-7b was significantly suppressed
($0.5 cycles) in cancerous compared to benign tissue (Fig. S3).
The balance of m(i)RNA expression in PCa and BPH was used for
assessment of the correlation coefficient (DCt PCalet-7b/HMGA1 - DCt
benign tissue let-7b/HMGA1). Pearson’s correlation coefficient con-
firmed a negative correlation between HMGA1 and let-7b
expression (r =20.71) suggesting that expression of HMGA1 in
primary PCa cases is at least partially regulated by let-7b (Fig. 5E).
Discussion
Over the last years specific miRNA signatures for PCa have
been described in several studies suggesting that miRNAs or
miRNA profiles can be used as diagnostic or prognostic markers in
this disease [5–9,11,12,15,16]. Nevertheless, there is not much
knowledge about the applicability of these as prognostic markers in
PCa. To screen for miRNAs that show specific expression for
high-risk disease we analyzed 13 high-risk PCa samples by a
microarray experiment. Initially, we compared the expression of
all 13 high-risk samples to the expression of 6 BPH samples and
found a miRNA expression profile that allowed a clear distinction
between the malignant and the benign disease. This scatter, with
the majority of miRNAs down-regulated in the high-risk PCa
samples, was comparable to results seen in further microarray
analyses using contemporary PCa study groups. Among the most
highly de-regulated microRNAs we primarily found miRNAs that
were previously described as PCa specific in other studies e.g. miR-
16, -26a, -125b, -143, -205, and miR-221, indicating that the high-
risk PCa cases show comparable miRNA expression alterations as
observed in contemporary PCa collectives [6–12].
Subsequently, we analyzed the miRNA expression alterations
among PCa samples with and without CF to screen for prognostic
Figure 4. Kaplan-Meier analysis for BCR and CF in a learning and testing high-risk PCa cohort. Kaplan-Meier analysis for biochemical and
clinical relapse of 98 and 92 patients with high-risk disease (cohort A and B). Groups were dichotomized in low and high let-7b and -7c expression.
Survival curves were generated using the Bioconductor package ‘‘survival’’. A. Kaplan Meier analysis of cohort A, the learning data set (n = 98). B.
Kaplan Meier analysis of cohort B, the testing data set (n = 92). Low let-7b expression is associated with BCR and CF.
doi:10.1371/journal.pone.0065064.g004
Table 3. Uni- and multivariate Cox regression analysis of high-risk cohort A.
variable + BCR univariate multivariate
n HR 95% CI p value HR 95% CI p value
let-7b dichot. high 47, low 51 0.36 0.161 - 0.823 0.02 0.44 0.193 - 1.022 0.05
let-7c dichot. high 7, low 91 2.81 0.840 - 9.388 0.09
Gleason Score 98 1.62 1.149 - 2.296 , 0.01 1.50 1.059 - 2.125 0.02
comb. pT 98 1.58 0.717 - 3.496 0.26
pre.PSA 98 1.01 0.999 - 1.021 0.07
variable + CF univariate multivariate
n HR 95% CI p value HR 95% CI p value
let-7b dichot. high 47, low 51 0.21 0.076 - 0.588 , 0.01 0.46 0.148 - 1.411 0.17
let-7c dichot. high 7, low 91 0.23 0.095 - 0.578 , 0.01 0.53 0.189 - 1.475 0.22
Gleason Score 98 2.93 1.741 - 4.916 , 0.01 2.15 1.276 - 3.615 , 0.01
comb. pT 98 2.05 0.737 - 5.683 0.17
pre.PSA 98 1.02 1.003 - 1.028 0.01 1.01 0.997 - 1.024 0.13
doi:10.1371/journal.pone.0065293.t003
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relevant miRNAs. Interestingly, hierarchical clustering of micro-
array data using a selected set of miRs differentially expressed in
BPH and PCa samples generated a tree with additional separation
of these both PCa groups suggesting that high-risk PCa cases with
early CF could be characterized by a distinct miRNA expression
profile. As expected from these results, we found seven miRNAs
that were differentially expressed between both PCa groups and
the non-malignant BPH samples. Three of these, namely miR-361,
-515-3 and -515-5, have not been described as oncomiRs until
now and their relevance in development and progression of PCa
remains to be tested in the future. Four other miRNAs (miR-146b,
-181b, let-7a and let-7c) are known oncogenic or tumor suppressor
miRNAs [30–33]. Our results demonstrate that miR-146b and -
181b are down-regulated in all PCa cases, but showed up-
regulation when we compared expression in PCa patients with CF
to patients with CPFS. These results are supported by studies
implicating that miR-181b up-regulation has prognostic effects in
cancer patients: Expression of miR-181 is significantly lower in
low-risk myelodysplastic syndrome (MDS), whereas patients with
high-risk MDS show an elevated expression of this miRNA [30]. It
was also demonstrated that squamous cell lung cancer patients
with high miR-146b expression have significantly worse overall
survival compared to patients with low expression [31]. Moreover,
down-regulation of miR-146b is described to correlate with
development of hormone refractory PCa [32]. Altogether, these
results implicate that deregulation of miR-181b or miR-146b might
be critically involved in development and progression of PCa.
However, our microarray-based miRNA expression study is
limited to a low number of analyzed cases, since it was primarily
designed as a screening approach. To test the clinical relevance of
the identified candidate miRNAs as prognostic markers larger
cohorts have to be tested. In addition our expression profiling is
limited by the use of BPH samples as control tissue. Based on the
highly invasive growth of various high-risk PCa cases (data not
shown) we were not able to isolate adjacent normal prostate tissue
with sufficient amounts of benign prostatic ducts for analyses. We
are aware that gene expression in BPH and cancer samples might
differ in regard to the different origin of the tissues (transition zone
vs. peripheral zone). Therefore, the results obtained by the
microarray study need to be interpreted cautiously and await
further experimental clarification by validation in independent
study cohorts and by functional studies in the future. However, our
current study focused on expression differences of let-7 family
members between samples of cancer patients with diverse outcome
rather than between cancerous and non-cancerous tissue.
Thus, we analyzed the expression of let-7 family members in a
large high-risk PCa collective to elucidate their potential role as
prognostic biomarker. As expected from the microarray data we
saw down-regulation of let-7a/b and -c in the majority of the high-
risk PCa cases analyzed. However, let-7a showed no clear impact
as prognostic marker in association analysis with clinical param-
eters. Even though, we found some correlation of low let-7c
expression with progression of PCa in a high-risk cohort, we could
not validate its role as prognostic marker for biochemical or
clinical progression using an independent testing cohort. We
therefore concluded that let-7c is frequently down-regulated in
PCa, but its clinical use as prognostic marker is very limited. With
regard to the role of let-7b as potential prognostic marker we
showed that patients with poor cancer characteristics like BCR or
CF have lower let-7b expression than patients with better clinical
outcome. As prognostic factor let-7b is independent from other
tested clinical factors and is closely related to PSA relapse and
recurrence of the disease. Altogether our findings suggest that
reduced expression of let-7-a/b and -c may play a role in
pathogenesis of prostate cancer and strongly support that reduced
let-7b expression may have a prognostic impact on biochemical
and clinical progression of PCa patients.
Our results implicating that let-7b is a useful biomarker to
predict clinical outcome are in line with studies in patients with
lung cancer. Takamizawa et al. analyzed tissue specimen of 143
lung cancer patients and found that patients, irrespective of disease
stage, had significantly worse post-operative survival, if let-7 was
down-regulated [19]. In addition, the potential of let-7 as
biomarker in various cancer types was recently implicated in a
systematic review demonstrating that let-7 is associated most
frequently and significantly with clinical outcome parameters in
cancer patients [34]. Martens-Uzunova and colleagues recently
also found let-7b to be significantly dys-regulated in PCa. They
Table 4. Uni- and multivariate Cox regression analysis of high-risk cohort B
variable + BCR univariate multivariate
n HR 95% CI p value HR 95% CI p value
let-7b dichot. high 44, low 48 0.25 0.125 - 0.493 , 0.01 0.30 0.152 - 0.610 , 0.01
let-7c dichot. high 5, low 87 0.00 0 - Inf 1.00
Gleason Score 92 1.54 1.169 - 2.022 , 0.01 1.36 1.012 - 1.820 0.04
comb. pT 92 2.20 1.221 - 3.968 , 0.01 1.24 0.640 - 2.398 0.53
pre.PSA 92 1.02 1.002 - 1.030 0.03 1.01 0.995 - 1.024 0.19
variable + CF univariate multivariate
n HR 95% CI p value HR 95% CI p value
let-7b dichot. high 44, low 48 0.24 0.084 - 0.703 , 0.01 0.23 0.078 - 0.700 , 0.01
let-7c dichot. high 5, low 87 3.67 0.485 - 27.80 0.21
Gleason Score 92 3.98 2.327 - 6.823 , 0.01 4.00 2.076 - 7.712 , 0.01
comb. pT 92 5.38 1.946 - 14.84 , 0.01 0.88 0.801 - 7.220 0.12
pre.PSA 92 1.02 1.00 - 1.041 0.05
doi:10.1371/journal.pone.0065293.t004
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Figure 5. HMGA1 is a direct target of let-7b in prostate cancer. A. 39UTR-sequence of binding sites for let-7b are indicated by vertical lines
towards HMGA1. B. qRT-PCR for let-7b and HMGA1 in untreated LNCaP and PC-3 cells. While let-7b shows higher expression in LNCaP compared to PC-
3 cells, HMGA1 expression shows inverse expression to let-7b. C. qRT-PCR and Western Blot analysis for HMGA1 using lysates from PC-3 cells
transiently transfected with pre2/anti-7b and negative control, respectively. Western Blot analysis was performed in two independent experiments.
Band intensity was measured by Image J in regard to housekeeping gene (b-Actin) band intensity. D. HMGA1 as target of let-7b. Luciferase construct
containing the 39UTR of HMGA1 were transfected with either pre–let-7b or pre-miR control into PC-3 cells. Relative expression of firefly luciferase was
determined 48 h post transfection and normalized to the transfection control. Error bars represent +/2 standard deviation and were calculated using
three independent experiments. E. Correlation analysis of HMGA1 and let-7b in vivo. In 21 pairs of PCa and adjacent benign tissue qRT-PCR analysis for
let-7b and HMGA1 were performed. Expression levels, normalized by RNU6B or b-Actin, were used to calculate the Pearson’s correlation coefficient
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created a miRNA-derived prognostic predictor, consisting of 25
miRNAs, including let-7b, that forecasted post-operative outcome
[10]. There is also clear evidence that members of the let-7 family
function as tumor suppressor in various cancer types and that
over-expression of let-7 suppresses growth of cancer cells in vivo
and in vitro including PCa [33]. More recently down-regulation of
let-7 was also demonstrated in prostate cancer stem cells indicating
an important role of this miRNA in tumorigenicity [25].
Altogether, this further supports our findings of let-7b being an
important predictor in clinical outcome in various cancer types
including PCa.
Down-regulation of several let-7 isoforms in high-risk disease
indicates their potential involvement in pathogenesis and progres-
sion of PCa. But how let-7 family members contribute to this is
poorly understood. It was previously shown that members of this
family simultaneously inhibit multiple oncogenic pathways in
cancer cells regulating the expression of relevant oncogenes like
cmyc, ras, CDC25A, and HMGA2 among others [22–24]. Moreover,
it was shown that the developmentally regulated RNA-binding
protein Lin28 selectively blocks the maturation of let-7 members,
which in turn repress the expression of Lin28 [35]. Based on the
connection of Lin28/let-7 several line of evidence support a role of
let-7 in stem cell biology and development. Deregulation of this
feedback mechanism is critical in controlling self-renewal, a
feature of cancer stem cells, which again is associated with
aggressiveness and progression in various cancer types [36,37].
Interestingly, it was shown that the developmentally regulated
gene HMGA1 is inversely correlated to let-7 in gastro-pancreatic
carcinoma and retinoblastoma [38,39]. HMGA1 is a member of
the non-histone nuclear binding proteins that alter chromatin
structure by inducing DNA confirmation and thus regulating the
transcriptional activity of several genes [40]. HMGA1 over-
expression plays a critical role in carcinogenesis and its up-
regulation was observed in many cancer entities like retinoblas-
toma, pancreatic, colorectal, lung and prostate cancer for example
[41–46]. Increased levels of HMGA1 were shown to be correlated
with the development of high-grade tumors in various cancer types
[47] and more recently it was demonstrated that overexpression of
HMGA1 is also associated with late stage prostate cancer [48].
Furthermore, over-expression of HMGA1 in PCa cells was
associated with enhanced proliferation and metastasis as well as
with development of androgen-independent growth [49]. Inter-
estingly, it was recently shown that HMGA1 is regulated by miR-
296, but not by let-7c [48]. We report in the current study that let-
7b represses HMGA1 expression by inhibiting translation and
additionally showed that HMGA1 is a direct target of let-7b. We
performed correlation studies ex vivo on primary PCa specimens
and confirmed an inverse relation between let-7b and its target
HMGA1. Based on these data we suggest that let-7b mediated
regulation of HMGA1 might partially explain the role of let-7b in
progression of PCa in context with its role in the development of
cancer stem cells. Identification of the interaction between let-7b
and HMGA1 will provide promising therapeutic opportunities in
PCa treatment.
In summary, we defined a distinct miRNA expression profile in
high-risk PCa with early CF. Our study further gives evidence that
one of the detected miRNAs, namely let-7b, works as a relevant
prognostic biomarker predicting clinical recurrence in high-risk
PCa. We identified the oncogene HMGA1 as direct target of let-7b
in PCa and found an inverse correlation of both in primary PCa
cases. It will be of great interest to understand the role of let-7b/
HMGA1 interaction for the development of cancer stem cells in
context with the regulation of others potential target genes of the
let-7 family members. Altogether, our study represents a basis to
develop novel strategies for the prognosis and therapy of PCa
patients at high risk for clinical recurrence of the disease.
Supporting Information
Figure S1 MiRNA expression in high-risk PCa (cohort
A) with early clinical failure. Venn diagram showing
relationships between human miRs that were expressed signifi-
cantly different (61.5 fold) in PCa group 1 vs. PCa group 2 vs.
BPH (adj p,0.05). Circles include numbers of up- or down-
regulated human miRs of each pair-wise comparison. Common
miRs between different comparisons are shown in intersections.
The table below lists all human miRs in which expression was
significantly different either: between (gr.1 vs. gr.2) (blue), (gr.2 vs.
BPH) (red), (gr.1 vs. BPH) (green), between (gr. 2 vs. BPH) and (gr.
1 vs. BPH) (yellow). (Complementary data to Fig. 2.) All miRNAs
are ranked based on the maximum expression fold change.
(XLSX)
Figure S2 Association of let-7a expression and clinical
data. Box- and whisker-plot show expression of let-7a in 98 high-
risk PCa tissue and 6 BPH specimens; assessed by qRT-PCR.
Subgroups are based on: N pathologic tumor features like Gleason
Score and pathological tumor stage (GS #7, pT #3a–light grey),
(GS $8, pT $3b–dark grey) and N clinic-pathological character-
istics like BCR, CF, CRD (no BCR/no CF/no CRD–light grey),
(BCR/CF/CRD–dark grey). Let-7a expression is not associated to
clinical data in high-risk PCa. Expression is shown as means with
error bars for standard deviation. p values were calculated using
the Welch 2 sample t-test.
(TIFF)
Figure S3 Let-7b expression in cancerous and adjacent
benign prostatic tissue (cohort C). Scatter Plot shows
expression of let-7b in 21 pairs of PCa tissue and adjacent benign
tissue. Median expression of let-7b is significantly lower in the
cancerous compared to the benign tissue. p values were calculated
using the Welch 2 sample t-test.
(TIFF)
Table S1 MiRNA expression in high-risk PCa (cohort A)
with early clinical failure compared to expression in
BPH. Microarray analysis of 6 BPH and 13 high-risk PCa tissue
specimens (cohort A). The table lists all 82 differentially expressed
miRNAs (fold change .1.5 and an adjusted p value ,0.05) The
majority of miRNAs showed decreased expression in high-risk
PCa compared to benign prostatic tissue.
(XLSX)
Table S2 MiRNA expression in high-risk PCa (cohort B)
and BPH. Table 2 summarizes the median expression of let-7b/c
in 6 BPH and 92 high-risk PCa samples and shows corresponding
standard deviation and the p value. The median expression of the
BPH samples was used as threshold. The percentage of PCa
samples with down-regulated let-7 expression are shown in the 6th
column of the table.
(XLSX)
(r = -0.71). B. + C. Relative expression is shown by means of 3 independent qRT-PCR experiments. *indicate statistically significant results (p,0.05). P
values were calculated using the Welch 2 sample t-test.
doi:10.1371/journal.pone.0065064.g005
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